Alexander Zehnder, CureVac CEO (Bernd Wei'brod/picture-alliance/dpa/AP Images)
July 3, 2024 04:20 AM EDTUpdated 06:45 AM
Deals

GSK re­works Cure­Vac deal, pay­ing $429M up­front to grab con­trol of mR­NA flu and Covid vac­cines 

Amber Tong

Senior Editor

GSK is hand­ing mR­NA vac­cine part­ner Cure­Vac €400 mil­lion ($429 mil­lion) up­front to take over full rights to the in­fluen­za and Covid vac­cine can­di­dates they …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Roche’s TIG­IT drug tiragolum­ab flunks an­oth­er Phase 3 lung can­cer test

Cir­cle Phar­ma rais­es $54M as part of Se­ries D while macro­cy­cles heat up

UK trade group slams No­vo, No­var­tis, Pfiz­er and Ot­su­ka for code breach­es

In biotech's un­even re­cov­ery, 50 star­tups raised megarounds in first half of 2024

Ex­perts want to make it eas­i­er to get RSV vac­cines. Did they make it hard­er in­stead?

Avid Bio’s 2024 rev­enue drops; Lotte Bio breaks ground on new $3.3B site 

A service from the Financial Times